Company / PP&E (Net)
Aquestive Therapeutics, Inc. PP&E (Net) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.9M
FY2025
5-year range
$3.8M / $5.1M
FY2021-FY2025
Trend
+2.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 8 years, ranging from $4M in FY2024 to $12M in FY2018.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -10.7%.
Declined from $4M to $4M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -1.6%
- 5-Year CAGR
- -10.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.7%, indicating a declining trend.
- In FY2025, pp&e (net) increased 2.5% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
- Lowest pp&e (net) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.9M | +2.5% |
| FY2024 | $3.8M | -9.1% |
| FY2023 | $4.2M | +2.3% |
| FY2022 | $4.1M | -19.2% |
| FY2021 | $5.1M | -26.5% |
| FY2020 | $6.9M | -29.3% |
| FY2019 | $9.7M | -20.3% |
| FY2018 | $12.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026